Pharming Group Q3 Earnings Forecast Lifted by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings estimates for Pharming Group in a report released on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.23 for the quarter, up from their previous forecast of $0.20. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Pharming Group’s Q4 2026 earnings at $0.24 EPS.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

A number of other equities research analysts also recently weighed in on PHAR. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research report on Wednesday, September 23rd. Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Trading Down 0.4%

PHAR opened at $9.95 on Thursday. The firm has a market cap of $704.26 million, a price-to-earnings ratio of 82.92 and a beta of -0.04. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. Pharming Group has a 12 month low of $9.62 and a 12 month high of $21.34. The stock has a fifty day moving average price of $11.21 and a 200-day moving average price of $13.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.